Abstract 1730P
Background
We hypothesized that PARP inhibitor Fluzoparib and preoperative radiotherapy (RT) will transform inoperable or borderline operable soft tissue sarcoma (STS) into an operable disease without increase of major wound complications (MWCs).
Methods
Primary or recurrent non-metastatic unresectable or borderline resectable extremity or trunk STS was enrolled. Patients received preoperative moderately fractionated RT of 43.5Gy in 15 fractions with concurrent and sequential Fluzoparib (100mg Bid for 10 weeks in total), followed by wide resection. NCI-CTC 5.0, RECIST 1.1 criteria, and EORTC-STBSG criteria was used to evaluate acute toxicities, clinical and pathological response. The primary endpoint was defined as MWCs as per the SR2 criteria within 4 months post-surgery.
Results
From Jun 2023 to Apr 2024, 49 patients were enrolled and 46 completed RT. Forty-six tumours (93.9%) were evaluated as unresectable or borderline resectable, with 40 tumor (81.6%) adjacent to or encircling key structures. There were 40, 6 and 3 patients having full-dose Fluzoparib, drug dose reduction and RT alone, respectively. The observed ≥Grade 3 Fluzoparib-related or RT-related acute toxicity is anemia in 1 patient, and skin reaction in two patients. There're 8 (8/43, 18.6%), 11 (25.6%) and 24 patients (55.8%) who achieved PR, tumor reduction by 20% and SD as per RECIST 1.1 at 4-6 weeks post-radiotherapy, respectively. Till May, 2024, there were 40 patients who underwent non-R2 limb-conserving surgery, with 26 R0 and 14 R1 resection (margin less than 1mm). Thirteen out of 37 patients (35.1%) with at least 6 weeks follow-up had MWCs, with 12 in lower extremity (12/33, 36.4%). As per the EORTC criteria, there were 1 (1/38, 2.6%), 7 (18.4%) and 10 (26.3%) patients achieving pathological Grade B, C, and D remission. In all, 28 patients (73.7%) had higher than 10% of hyalinization/fibrosis.
Conclusions
For patients with non-metastatic extremity or trunk STS, the combination of PARP inhibitor and pre-operative moderately fractionated RT is safe and well-tolerated, and make majority of tumors transformed into operable disease.
Clinical trial identification
NCT05938374.
Editorial acknowledgement
Funding
CAMS Innovation Fund for Medical Sciences (CIFMS) [grant number 2023-I2M-C&T-B-089] and the Beijing Hope Run Special Fund of Cancer Foundation of China [grant number LC2020A15].
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1362P - Evaluation of imaging-based prognostication (IPRO) for advanced non-small cell lung cancer (aNSCLC) using deep learning applied to computed tomography (CT)
Presenter: Omar Khan
Session: Poster session 06
1363P - An AI-derived tool to pre-screen lung cancer candidates for clinical trials
Presenter: Mihaela Aldea
Session: Poster session 06
1364P - Federated analysis of overall survival (OS) by location of metastases (mets) in patients (pts) with metastatic NSCLC (mNSCLC) from the Digital Oncology Network for Europe (DigiONE)
Presenter: Åsa Öjlert
Session: Poster session 06
1365P - Does cancer care differ for older adults with lung cancer living with and without Alzheimer disease and related dementias (ADRD)?
Presenter: Lorinda Coombs
Session: Poster session 06
1366P - Natural Language Processing (NLP) as promising artificial intelligence (AI) tool to improve patients (pts) enrollment in clinical trials (CT): Analysis in real-world conditions on a lung cancer cohort
Presenter: Julien Mazieres
Session: Poster session 06
1367P - Sex disparities in patient and tumour characteristics, and overall survival in advanced non-small cell lung cancer (NSCLC) within the precision oncology era: A Danish nationwide observational study
Presenter: Matilde Frost
Session: Poster session 06
1368P - Correlation between depth of response at 6 months and survival in patients (pts) with metastatic non-small cell lung carcinoma (mNSCLC): SPORE trial
Presenter: Fabien Moinard-Butot
Session: Poster session 06
1369P - Trilaciclib combined with intraventricular injection chemotherapy in the treatment of advanced NSCLC with leptomeningeal metastasis: A prospective, single-arm, phase II clinical trial
Presenter: Shen Cun Fang
Session: Poster session 06
1370P - Survival of de novo metastatic non-small cell lung cancer according to biomarker status in Denmark and Norway: A register-based cohort study
Presenter: Johan Liseth Hansen
Session: Poster session 06